share_log

Asia Green Biotechnology Corp. Announces Delay in Filing of Annual Financial Statements and Application for Management Cease Trade Order

Asia Green Biotechnology Corp. Announces Delay in Filing of Annual Financial Statements and Application for Management Cease Trade Order

亚洲绿色生物技术公司宣布延迟提交年度财务报表和申请管理层停止贸易令
Accesswire ·  04/17 17:10

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE OR FOR DISSEMINATION IN THE UNITED STATES

不用于分发给美国新闻通讯社或在美国传播

CALGARY, AB / ACCESSWIRE / April 17, 2024 / Asia Green Biotechnology Corp. ("Asia Green" or the "Company")
(CSE:ASIA) announces that it is unlikely to meet the filing date of April 29, 2024 ("Filing Date"),
as required under National Instrument 51-102, for filing of the following continuous disclosure documents (collectively, the "Documents"):

艾伯塔省卡尔加里/ACCESSWIRE/2024年4月17日/亚洲绿色生物技术公司(“Asia Green” 或 “公司”)
(CSE: ASIA)宣布,它不太可能在2024年4月29日的申请日期(“申请日期”)之前完成,
根据国家仪器51-102的要求,提交以下持续披露文件(统称为 “文件”):

  • The Company's Annual Audited Financial Statements for the year ended December 31, 2023,
    as required by section 4.2 of National Instrument 51-102 - Continuous Disclosure Obligations
    ("NI 51-102"); and
  • The Company's Management Discussion & Analysis for the year ended December 31, 2023,
    as required by section 5.1(2) of NI 51-102.
  • CEO and CFO certificates relating to the Audited Annual Financial Statements, as required by
    NI 51-102.
  • 公司截至2023年12月31日止年度的年度经审计的财务报表,
    按照《国家仪器》51-102 第 4.2 节的要求- 持续披露义务
    (“NI 51-102”);以及
  • 公司截至2023年12月31日止年度的管理层讨论与分析,
    按照 NI 51-102 第 5.1 (2) 节的要求。
  • 根据要求,与经审计的年度财务报表相关的首席执行官和首席财务官证书
    在 51-102 年。

The potential default is due, in part, to business and administrative disruption experienced by the Company in respect of the Company's auditor's inability to complete the work required to issue the Documents as a result of an investigation of the former auditor's activities on matters unrelated to the Company.

潜在的违约在一定程度上是由于对前审计师在与公司无关的事项上的活动进行调查后,公司的审计师无法完成发布文件所需的工作,因此公司遭受了业务和管理混乱。

The Company has now engaged new auditors to complete the work and it is expected the Documents will be filed within 30-60 days of the Filing Date, if not before.

该公司现已聘请了新的审计师来完成工作,预计文件将在提交日期后的30-60天内提交,如果不是在此之前。

Accordingly, and as a precautionary measure, the Company has applied to the Alberta Securities Commission ("ASC") for a Management Cease Trade Order ("MCTO")that will prohibit the management of the Company from trading in the securities of the Company until such time as the Documents are filed. No decision has yet been made by the ASC on this application. The ASC may grant the application and issue the MCTO or it may impose an issuer cease trade order if the Documents are not filed in a timely fashion.

因此,作为预防措施,公司已向艾伯塔省证券委员会(“ASC”)申请管理停止交易令(“MCTO”),该令将禁止公司管理层在文件提交之前交易公司的证券。澳大利亚证券交易委员会尚未就该申请做出任何决定。如果文件未及时提交,澳大利亚证券交易委员会可以批准申请并签发MCTO,也可以下达发行人停止交易令。

During any period of default and until filing of the Documents, the Company intends to satisfy the provisions of the alternative information guidelines as required by National Policy 12-203 Management Cease Trade Orders.

在任何违约期间以及在提交文件之前,公司都打算按照国家政策12-203的要求满足替代信息指南的规定 管理层停止交易订单

Until the Company has filed the Documents, members of the Company's management and other insiders are subject to an insider trading black-out policy as per its internal Insider Trading Policy that is consistent with the principles in Section 9 of National Policy 11-207 - Failure-to-File Cease Trade Orders and Revocations in Multiple Jurisdictions. The Company confirms that, other than as disclosed in prior press releases and material change reports, there have been no material business developments since the filing on November 29, 2023 of the Company's latest interim financial reports for the period ended September 30, 2023.

在公司提交文件之前,根据其内部内幕交易政策,公司管理层成员和其他内部人士将受到内幕交易封锁政策的约束,该政策符合国家政策11-207第9节中的原则- 未能在多个司法管辖区提交停止贸易令和撤销令。公司证实,除了先前的新闻稿和重大变动报告中披露的内容外,自2023年11月29日公司提交截至2023年9月30日的最新中期财务报告以来,没有任何重大的业务发展。

For further information, contact:

欲了解更多信息,请联系:

Asia Green Biotechnology Corp.
David E.T. Pinkman (CEO)
T: 403 863-6034
E: david.pinkman@asiagreenbiotechnology.com

亚洲绿色生物技术公司
大卫 E.T. Pinkman(首席执行官)
电话:403 863-6034
E: david.pinkman@asiagreenbiotechnology.com

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

CSE及其监管服务提供商(该术语在CSE的政策中定义)均不对本新闻稿的充分性或准确性承担责任。

Caution Regarding Forward-Looking Information Forward-looking statements - Certain information set forth in this news release may contain forward-looking statements that involve substantial known and unknown risks and uncertainties. Forward-looking statements are often, but not always, identified by words such as "believes", "may", "likely", "plans", or similar words. Forward- looking statements included in this news release include statements with respect to activities in Zimbabwe. These forward-looking statements are subject to numerous risks and uncertainties, certain of which are beyond the control of the Company, including, but not limited to the impact of general economic conditions, industry conditions, currency fluctuations, and dependence upon regulatory approvals. The Company does not assume any obligation to update the forward-looking statements to reflect changes in assumptions or circumstances other than as required by applicable law.

前瞻性信息注意前瞻性陈述——本新闻稿中列出的某些信息可能包含涉及大量已知和未知风险和不确定性的前瞻性陈述。前瞻性陈述通常以 “相信”、“可能”、“可能”、“计划” 或类似词语来识别,但并非总是如此。本新闻稿中包含的前瞻性声明包括有关津巴布韦活动的声明。这些前瞻性陈述受到许多风险和不确定性的影响,其中一些风险和不确定性是公司无法控制的,包括但不限于总体经济状况、行业状况、货币波动和对监管批准的依赖的影响。除适用法律要求外,公司不承担任何义务更新前瞻性陈述以反映假设或情况的变化。

SOURCE: Asia Green Biotechnology Corp.

来源:亚洲绿色生物技术公司


声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发